Anxiety News and Research

Latest Anxiety News and Research

USFDA approves Sun Pharma's generic Xanax ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

18 Jun 2010

Research examines relationship between body-image distortion and weight-loss behaviors

Normal weight and underweight teenage girls who falsely believe they are overweight are at significantly greater risk of succumbing to unnecessary and unsafe weight-loss behaviors than girls who can accurately assess their weight status, according to new research by a University of Illinois expert in eating disorders and body-image perception.

18 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

States want Congress to keep extra Medicaid money flowing

Illinois will face a $750 million shortfall in the fiscal year beginning in July if Congress doesn't extend increased Medicaid funding, originally part of last year's economic stimulus, Illinois Statehouse News reports. "The increased Medicaid reimbursements stand as a national issue as the recession lingers. Thirty states have crafted budgets for the fiscal year set to begin July 1 based on an extension of the increased payments, according to the National Conference of State Legislatures" (Massingale, 6/16).

18 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Scientists identify symptoms associated with late-onset hypogonadism

Scientists have for the first time identified the symptoms associated with what has been termed late-onset hypogonadism or 'male menopause' caused by a reduction in testosterone production in ageing men.

17 Jun 2010

CAMFT listed in 2010 Associations Advance America Honor Roll

The California Association of Marriage and Family Therapists has been named to the 2010 Associations Advance America Honor Roll, a national awards competition sponsored by the American Society of Association Executives & The Center for Association Leadership, Washington, D.C.

16 Jun 2010

Stress-related psychiatric disorders more common among women: Study

There may be a biological reason why depression and other stress-related psychiatric disorders are more common among women compared to men. Studying stress signaling systems in animal brains, neuroscience researchers found that females are more sensitive to low levels of an important stress hormone and less able to adapt to high levels than males.

16 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

New data shows Ohio children with special health care needs have inadequate insurance coverage

A third of Ohio children with special health care needs have unstable or inadequate insurance coverage despite the fact that they may qualify for government health programs, according to a new data analysis by the Child Policy Research Center at Cincinnati Children's Hospital Medical Center.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Orasi Medical today announced that it has entered an agreement with H. Lundbeck A/S to study the effect of Lundbeck central nervous system compounds on the human brain.

15 Jun 2010

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

15 Jun 2010

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.

15 Jun 2010

Retiring health care professionals may strain an overburdened system

The Washington Post: "Since the passage of the health-care law in March, much has been said about the coming swarm of millions of retiring baby boomers and the strain they will put on the nation's health-care system. That's only half the problem. Overlooked in the conversation is a particular group of boomers: doctors and nurses who are itching to call it quits.

15 Jun 2010

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

Apple juice can be a useful supplement for calming the declining moods that are part of the normal progression of moderate-to-severe Alzheimer's Disease, according to a study in American Journal of Alzheimer's Disease and Other Dementias, published by SAGE.

15 Jun 2010

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Genzyme Corporation announced today that its alemtuzumab for multiple sclerosis development program has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). This designation covers patients with relapsing-remitting forms of the disease.

15 Jun 2010

Olfactory function tests could help in treating patient in early stages of PD

A fast, simple and non invasive test of the ability to smell may be an important tool to screen people who are likely to develop Parkinson's disease, in which motor symptoms only become evident at a later stage of the disease, a German scientist will tell the annual conference of the European Society of Human Genetics today (Saturday).

14 Jun 2010

Anxiety News and Research

Latest Anxiety News and Research

USFDA approves Sun Pharma's generic Xanax ANDA

Research examines relationship between body-image distortion and weight-loss behaviors

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

States want Congress to keep extra Medicaid money flowing

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Scientists identify symptoms associated with late-onset hypogonadism

CAMFT listed in 2010 Associations Advance America Honor Roll

Stress-related psychiatric disorders more common among women: Study

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

New data shows Ohio children with special health care needs have inadequate insurance coverage

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Orasi Medical signs agreement to study effect of Lundbeck CNS compounds on human brain

Depression and other stress-related psychiatric disorders in women may have biological basis: Research

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

Retiring health care professionals may strain an overburdened system

Apple juice calms declining moods that are part of normal progression of AD: AJADD study

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

Olfactory function tests could help in treating patient in early stages of PD

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Anxiety News and Research

Latest Anxiety News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in